# Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer

Source: https://onco.cc/trials/nct06928584/  
OnCo record `nct06928584` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine, fluorouracil (5-FU), leucovorin (folinic acid), fOLFOX (5-FU, leucovorin, oxaliplatin) and other drugs in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer is a phase 2, randomised interventional study registered as NCT06928584 by Fudan University, with a registry enrolment figure of 221 participants, started 2025-03-10 and due to reach its primary completion in 2030-03-10. Interventions recorded: Conventional Radiotherapy; Capecitabine; 5-fluorouracil; folinic acid; Oxaliplatin; Irinotecan; Cetuximab; Bevacizumab; Hypofractionated radiotherapy; PD-1 antibody. Conditions listed: Locally Recurrent Rectal Cancer. Primary outcome: Progression-Free Survival. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06928584
- Phase: 2
- Setting: Multicenter, Randomized, Phase II Trial of Neoadjuvant Hypofractionated Radiotherapy Plus Immunotherapy and First-line Therapy Versus Conventional Radiotherapy Plus First-line Therapy in pMMR Locally Recurrent Rectal Cancer (TORCH-R2)
- Sponsor: Fudan University
- Enrolled: 221

## Sources

- ClinicalTrials.gov NCT06928584: https://clinicaltrials.gov/study/NCT06928584

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06928584.json